Inflammation During COVID-19 Hospitalization Linked to Mortality
Inflammation during hospitalization for an initial COVID-19 episode is associated with an increased risk for 12-month mortality.
Inflammation during hospitalization for an initial COVID-19 episode is associated with an increased risk for 12-month mortality.
Two 50-µg doses of the mRNA-1273 vaccine are safe and effective for children aged 6 to 11 years.
For patients hospitalized with COVID-19, persistent viral shedding occurs frequently and is associated with in-hospital delirium and increased six-month mortality.
Survivors of COVID-19 hospitalization have improvement in physical and mental health over two years, but the burden of symptomatic sequelae remains high.
It is a number many Americans have grimly expected but may still find hard to comprehend: More than 1 million Americans have died from COVID-19.
Unvaccinated COVID-19 patients with preexisting myocardial injury have a substantially greater risk for six adverse COVID-19 outcomes.
Provisional data from the National Center for Health Statistics at the US Centers for Disease Control and Prevention show that US overdose deaths in 2021 increased at half the pace of 2020 but are still up 15%.
The US Food & Drug Administration announced that it is continuing its efforts to boost the country’s supply of infant formula.
For adults hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, encephalopathy at admission is the most common serious neurologic manifestation, all of which are associated with worse outcomes.
Black children with type 1 diabetes (T1D) experience disparities in health outcomes compared with other racial and ethnic groups with similar neighborhood opportunity profiles.